NZ754922A - Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof - Google Patents

Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof

Info

Publication number
NZ754922A
NZ754922A NZ754922A NZ75492218A NZ754922A NZ 754922 A NZ754922 A NZ 754922A NZ 754922 A NZ754922 A NZ 754922A NZ 75492218 A NZ75492218 A NZ 75492218A NZ 754922 A NZ754922 A NZ 754922A
Authority
NZ
New Zealand
Prior art keywords
kinase inhibitors
compounds
pharmaceutical use
janus kinase
novel amino
Prior art date
Application number
NZ754922A
Other languages
English (en)
Inventor
Lars Rasmussen
Jens Larsen
Mogens Larsen
Andreas Ritzen
Tine Marianne Duus
Original Assignee
Aqilion Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aqilion Ab filed Critical Aqilion Ab
Publication of NZ754922A publication Critical patent/NZ754922A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ754922A 2017-01-11 2018-01-10 Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof NZ754922A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17151020 2017-01-11
PCT/EP2018/050548 WO2018130563A1 (en) 2017-01-11 2018-01-10 Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
NZ754922A true NZ754922A (en) 2025-11-28

Family

ID=57777557

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ754922A NZ754922A (en) 2017-01-11 2018-01-10 Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof

Country Status (26)

Country Link
US (1) US10703751B2 (https=)
EP (1) EP3568396B1 (https=)
JP (1) JP7009504B2 (https=)
KR (1) KR102548543B1 (https=)
CN (1) CN110167938B (https=)
AU (1) AU2018208516B2 (https=)
CA (1) CA3045567A1 (https=)
CY (1) CY1123864T1 (https=)
DK (1) DK3568396T3 (https=)
ES (1) ES2846741T3 (https=)
HR (1) HRP20210095T1 (https=)
HU (1) HUE052720T2 (https=)
IL (1) IL267829B (https=)
LT (1) LT3568396T (https=)
MX (1) MX389378B (https=)
MY (1) MY195576A (https=)
NZ (1) NZ754922A (https=)
PL (1) PL3568396T3 (https=)
PT (1) PT3568396T (https=)
RS (1) RS61317B1 (https=)
RU (1) RU2019125177A (https=)
SI (1) SI3568396T1 (https=)
TW (1) TWI760419B (https=)
UA (1) UA123972C2 (https=)
WO (1) WO2018130563A1 (https=)
ZA (1) ZA201904190B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3555097T (lt) 2016-12-16 2022-08-25 Janssen Pharmaceutica Nv Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Jak激酶家族之小分子抑制劑
JP2021528479A (ja) * 2018-07-06 2021-10-21 レオ ファーマ アクティーゼルスカブ ヤヌスキナーゼ阻害剤としての新規アミノ−イミダゾピリミジン誘導体およびその製薬学的用途
AU2020337720B2 (en) * 2019-08-30 2024-02-15 Tsd Life Sciences Co., Ltd. Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient
BR112023018286A2 (pt) 2021-03-11 2023-10-31 Janssen Pharmaceutica Nv Lorpucitinib para uso no tratamento de distúrbios mediados por jak
CN119569971B (zh) * 2025-02-07 2025-05-27 吉林大学 一种用于蛋白质磷酸化和棕榈酰化修饰同时筛选的Janus材料的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100375A1 (en) * 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
EP2523957A1 (en) 2010-01-12 2012-11-21 F. Hoffmann-La Roche AG Tricyclic heterocyclic compounds, compositions and methods of use thereof
CN103168032A (zh) * 2010-08-05 2013-06-19 安美基公司 抑制间变性淋巴瘤激酶的苯并咪唑和氮杂苯并咪唑化合物
EP2518071A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
UY34616A (es) 2012-02-10 2013-09-30 Galapagos Nv Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
CN104918945B (zh) 2012-11-01 2018-01-05 因赛特公司 作为jak抑制剂的三环稠合噻吩衍生物
RU2015118647A (ru) * 2012-11-20 2017-01-10 Дженентек, Инк. Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
CN104098563A (zh) 2013-04-02 2014-10-15 山东亨利医药科技有限责任公司 Jnk抑制剂化合物
CN106687462A (zh) 2014-04-30 2017-05-17 因赛特公司 Jak1抑制剂的制备方法以及其新形式
KR102399848B1 (ko) 2016-10-03 2022-05-19 하이라이트ll 파머슈티컬 (하이난) 컴퍼니, 리미티드 신규한 jak1 선택적 억제제 및 그 용도
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز

Also Published As

Publication number Publication date
CA3045567A1 (en) 2018-07-19
CY1123864T1 (el) 2022-05-27
SI3568396T1 (sl) 2021-04-30
CN110167938B (zh) 2024-06-14
ES2846741T3 (es) 2021-07-29
ZA201904190B (en) 2020-10-28
JP2020504186A (ja) 2020-02-06
WO2018130563A1 (en) 2018-07-19
TW201829407A (zh) 2018-08-16
BR112019014191A2 (pt) 2020-02-11
IL267829B (en) 2022-02-01
PL3568396T3 (pl) 2021-05-31
TWI760419B (zh) 2022-04-11
PT3568396T (pt) 2021-02-09
KR20190103231A (ko) 2019-09-04
UA123972C2 (uk) 2021-06-30
CN110167938A (zh) 2019-08-23
HUE052720T2 (hu) 2021-05-28
IL267829A (en) 2019-09-26
EP3568396B1 (en) 2020-11-11
AU2018208516B2 (en) 2021-07-08
AU2018208516A1 (en) 2019-07-11
RS61317B1 (sr) 2021-02-26
KR102548543B1 (ko) 2023-06-29
US20190367512A1 (en) 2019-12-05
DK3568396T3 (da) 2021-01-18
US10703751B2 (en) 2020-07-07
MX389378B (es) 2025-03-20
MY195576A (en) 2023-02-02
HRP20210095T1 (hr) 2021-03-05
RU2019125177A (ru) 2021-02-15
JP7009504B2 (ja) 2022-01-25
MX2019008331A (es) 2020-01-14
RU2019125177A3 (https=) 2021-05-11
EP3568396A1 (en) 2019-11-20
LT3568396T (lt) 2021-02-10

Similar Documents

Publication Publication Date Title
NZ754922A (en) Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
NZ777871A (en) Small molecule modulators of il-17
PH12020551305A1 (en) Pharmaceutical Compounds
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12022551226A1 (en) Pyrrolotriazine compounds acting as mnk inhibitor
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
PH12021551873A1 (en) Hydroxypyridoxazepines as nrf2 activators
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
SA522431777B1 (ar) مشتقات ألفا -d- جالاكتو بيرانوسيد
NZ762437A (en) Novel heterocyclic compounds as cdk8/19 inhibitors
PH12019500569A1 (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
WO2020247298A3 (en) 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
MX2022012881A (es) Inhibidores de replicacion del virus de inmunodeficiencia humana.
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: AQILION AB, SE

Effective date: 20221214

PSEA Patent sealed